Insider filing · CADL

Paul B Manning bought $3.0M of Candel Therapeutics (CADL)

Executed Feb 23, disclosed Feb 27, 3 days later, against a two-business-day limit.

Over the 21 trading sessions from the disclosed entry session (Feb 26), the stock returned -5.8% (delay-adjusted); from the execution session (Feb 23), -1.2%. Derived: entry at the session's open, exit at the close 20 sessions later.

PM Paul B Manning Director profile →

Paul B Manning (Director) filed 3 Form 4 reports in the trailing twelve months (2 purchases, 1 sale, 1 filed past the two-business-day deadline), most often in Candel Therapeutics, Inc. (CADL). Across 2 priced purchase filings, the average 21-session return was +36.0% from execution and +33.7% from disclosure (delay-adjusted; derived). The largest single filing was $17.5M of VRCA (4,126,142 sh across 2 lots, as filed), executed Nov 25 2025.

CADL Candel Therapeutics, Inc. CADL · Healthcare · 17 filings in 24 months ticker →

Healthcare · Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→